PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced new results from the Phase 3 PALISADE study and the open-label extension from the Phase 2 MUIR and ...

MALVERN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for ...

FINTEPLA is approved by the U.S. Food and Drug Administration (FDA) for the treatment of seizures associated with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) in patients two years of age ...

Safety data over 52 weeks: treatment was well tolerated and consistent with 14-week blinded safety data Preliminary analyses presented at the European Academy of Dermatology & Venereology (EADV) ...

– Substantial and durable reductions in convulsive seizure frequency observed in patients treated with 2 or 3 doses of 70mg followed by 45mg maintenance dosing on top of the best available ...

Ponsegromab treatment led to sustained weight gain and GDF-15 suppression over 64 weeks in cancer-associated cachexia patients. Patients initially on placebo gained weight after switching to ...

Jasper Therapeutics (JSPR) announced that it is commencing an open-label extension study in chronic urticarias that will roll over patients from the BEACON and SPOTLIGHT studies upon completion of ...

Acoramidis showed a 42% reduction in all-cause mortality and cardiovascular hospitalizations at 30 months compared to placebo in the ATTRibute-CM trial. Continuous acoramidis use resulted in a 48.2% ...

The MarketWatch News Department was not involved in the creation of this content. -- Adolescents in a long-term, open-label extension study receiving a twice-daily low dose of repinatrabit achieved ...

Please provide your email address to receive an email when new articles are posted on . Researchers used data from the GRIPHON study and open-label extension study. The median selexipag dose was 1,000 ...

Five abstracts accepted including Late-breaking Science oral and poster presentations of Phase 3 X-TOLE2 study results for azetukalner in focal ...